Advanced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Frederick Locke

Internal Medicine
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Offers Telehealth
21 Years of Experience
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Frederick Locke is an Internal Medicine provider in Tampa, Florida. Dr. Locke has been practicing medicine for over 21 years and is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 251 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Locke has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Fludarabine, Melphalan
Study Phase: Phase 2
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Biological
Study Drug: Gamma Delta T-Cell Infusion
Study Phase: Phase 1
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 1
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pacritinib, Sirolimus, Tacrolimus
Study Phase: Phase 1/Phase 2
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drugs: BMS-986004, Sirolimus, Tacrolimus
Study Phase: Phase 1
A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia
A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Phase: Early Phase 1
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 14, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: Survivin Vaccine, Prevnar 13, Granulocyte-colony Stimulating Factor
Study Phase: Early Phase 1
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 01, 2022
Intervention Type: Drug
Study Drug: Panobinostat
Study Phase: Phase 2
Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease
Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drug: Ofatumumab
Study Phase: Phase 1/Phase 2
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug, Procedure, Radiation
Study Phase: Phase 1
A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drugs: Panobinostat, Sirolimus, Tacrolimus
Study Phase: Phase 2
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
View 11 Less Clinical Trials

251 Total Publications

Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis.
Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis.
Journal: Journal of managed care & specialty pharmacy
Published: October 31, 2025
Similar Doctors
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Olga V. Klinkova
Internal Medicine | Hospital Medicine
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Olga V. Klinkova
Internal Medicine | Hospital Medicine

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Olga Klinkova is a Hospital Medicine provider in Tampa, Florida. Dr. Klinkova is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Febrile Neutropenia, MAGIC Syndrome, Smoldering Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), and Tissue Biopsy. Dr. Klinkova is currently accepting new patients.

Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Frederick C. Polsky
Internal Medicine
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Frederick C. Polsky
Internal Medicine

Optumcare Florida, LLC

5130 Sunforest Dr, Suite 300, 
Tampa, FL 
 (9.1 miles away)
727-824-0780
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frederick Polsky is a primary care provider, practicing in Internal Medicine in Tampa, Florida. Dr. Polsky is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD), Collagenous Colitis, Jock Itch, and Familial Hypertension. Dr. Polsky is currently accepting new patients.

Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Neha R. Verma
Internal Medicine
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Neha R. Verma
Internal Medicine

H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-860-2778
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neha Verma is a primary care provider, practicing in Internal Medicine in Tampa, Florida. Dr. Verma is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Lung Cancer, Drug-Induced Thrombocytopenia, Primary Lymphoma of the Brain, Gastrostomy, and Bone Marrow Aspiration. Dr. Verma is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Locke's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile